Rich Insights into the Systemic Lupus Erythematosus Market, Epidemiology Segmentation, Pipeline therapies and Major Players in the Industry
iCrowd Newswire
29 Apr 2021, 21:25 GMT+10
Rich Insights into the Systemic Lupus Erythematosus Market, Epidemiology Segmentation, Pipeline therapies and Major Players in the Industry
DelveInsight s
Key Highlights from the
Total diagnosed prevalent cases of SLE in the 7MM was found to be
484,213 in 2017. Among all the countries, the estimates show a higher population of SLE in the United States with over
259,000 cases in 2017.
According to DelveInsight estimates, among the 7MM, Japan had the lowest diagnosed prevalent population of SLE in 2017. The appearance of the SLE is independent of the age, although the onset is usually observed in persons aged 20-30 years.
Rich Insights into the Systemic Lupus Erythematosus Market, Epidemiology Segmentation, Pipeline therapies and Major Players in the Industry
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
email article
On the heels of the announcement of depressed antibody responses to COVID-19 vaccines in transplanted patients, the first question that came to my mind as a practicing rheumatologist was: Does this important and frightening finding also apply to our patients with autoimmune diseases on immunosuppressants?
Fortunately, we have also been studying patients with rheumatic and musculoskeletal diseases (RMD) in our national study of vaccine immune responses. Among 123 COVID-19-naive patients with autoimmune disease inflammatory arthritis, systemic lupus erythematosus, or other connective tissue diseases who received a first dose of mRNA vaccine, 74% had detectable antibodies to SARS-CoV-2.
Share this article
LAS VEGAS, April 19, 2021 /PRNewswire/ DelveInsight s
Global Kinase Inhibitor in Autoimmune Diseases Market report provides a thorough comprehension and the Global Kinase Inhibitor in Autoimmune Diseases market trends across the globe. The Global Kinase Inhibitor in Autoimmune Diseases market report also proffers an analysis of the current Global Kinase Inhibitor in Autoimmune Diseases treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the vital takeaways of the
Pfizer, Eli Lilly, AbbVie, Gilead Sciences, Astellas Pharma, Japan Tobacco and Torii Pharmaceutical, Reistone Biopharma, Bristol Myers Squibb, Galapagos NV, Aclaris Therapeutics, Taiho Pharma, Oncostellae, Novartis Pharmaceuticals, Aclaris Therapeutics, Theravance Biopharma and Janssen (Johnson & Johnson), Kadmon Pharmaceuticals, Incyte Corporation, and others are the major players working in Global Kinase Inhibitor in Autoimmune Diseases Market r
email article
Each one-unit increase on a disease activity score during the first year after enrollment into a systemic lupus erythematosus (SLE) cohort was associated with a significant increased risk for death and organ damage during subsequent follow-up, researchers reported.
On a multivariable analysis, a one-unit increase on the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) was associated with a 22% higher risk of death during an average 7 years of follow-up (HR 1.22, 95% CI 1.13-1.32,
P
vimarsana © 2020. All Rights Reserved.